{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T19:06:42Z","timestamp":1793128002458,"version":"4.5.0"},"reference-count":131,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T00:00:00Z","timestamp":1771891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T00:00:00Z","timestamp":1771891200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr HIV\/AIDS Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose of Review<\/jats:title>\n                    <jats:p>People living with HIV (PLWH) on contemporary antiretroviral therapy experience high rates of overweight\/obesity, which predisposes to cardiometabolic disease and multiple other conditions with negative health consequences in this aging population. We aim to summarize the epidemiology and pathophysiology of obesity in PLWH and review recent advances in the therapeutic management of obesity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent Findings<\/jats:title>\n                    <jats:p>The prevalence of overweight\/obesity in PLWH mirrors long-standing trends in the general population. Obesity and weight gain have a complex, multifactorial pathogenesis and directly mediate detrimental metabolic changes that are common in PLWH. While lifestyle changes are important, surgical weight loss and recent advances in medical therapeutics are more effective at reducing obesity and obesity-related complications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>Obesity in PLWH substantially increases the risk for cardiometabolic complications and poor health outcomes. Surgical and medical weight loss interventions are effective treatments to reduce obesity and obesity-related complications, though further research in PLWH is needed to define optimal management.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11904-026-00776-1","type":"journal-article","created":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T04:25:08Z","timestamp":1771907108000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Obesity and Weight Management in HIV: Epidemiology, Complications, and Emerging Treatments"],"prefix":"10.1007","volume":"23","author":[{"given":"Luke","family":"Pryke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John R.","family":"Koethe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Bailin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,24]]},"reference":[{"issue":"11","key":"776_CR1","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1161\/CIRCULATIONAHA.117.033369","volume":"138","author":"ASV Shah","year":"2018","unstructured":"Shah ASV, Stelzle D, Lee KK, Beck EJ, Alam S, Clifford S, et al. Global burden of atherosclerotic cardiovascular disease in people living with HIV: systematic review and meta-analysis. Circulation. 2018;138(11):1100\u201312. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.117.033369.","journal-title":"Circulation"},{"issue":"6","key":"776_CR2","doi-asserted-by":"publisher","first-page":"e207954","DOI":"10.1001\/jamanetworkopen.2020.7954","volume":"3","author":"JL Marcus","year":"2020","unstructured":"Marcus JL, Leyden WA, Alexeeff SE, Anderson AN, Hechter RC, Hu H, et al. Comparison of overall and Comorbidity-Free life expectancy between insured adults with and without HIV Infection, 2000\u20132016. JAMA Netw Open. 2020;3(6):e207954. https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.7954.","journal-title":"JAMA Netw Open"},{"issue":"21","key":"776_CR3","doi-asserted-by":"publisher","first-page":"e984","DOI":"10.1161\/CIR.0000000000000973","volume":"143","author":"TM Powell-Wiley","year":"2021","unstructured":"Powell-Wiley TM, Poirier P, Burke LE, Despres JP, Gordon-Larsen P, Lavie CJ, et al. Obesity and Cardiovascular Disease: a scientific statement from the American Heart Association. Circulation. 2021;143(21):e984\u20131010. https:\/\/doi.org\/10.1161\/CIR.0000000000000973.","journal-title":"Circulation"},{"issue":"2","key":"776_CR4","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1002\/hep.23280","volume":"51","author":"E Fabbrini","year":"2010","unstructured":"Fabbrini E, Sullivan S, Klein S. Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. Hepatology. 2010;51(2):679\u201389. https:\/\/doi.org\/10.1002\/hep.23280.","journal-title":"Hepatology"},{"issue":"46","key":"776_CR5","doi-asserted-by":"publisher","first-page":"e5399","DOI":"10.1097\/MD.0000000000005399","volume":"95","author":"KM Erlandson","year":"2016","unstructured":"Erlandson KM, Zhang L, Lake JE, Schrack J, Althoff K, Sharma A, et al. Changes in weight and weight distribution across the lifespan among HIV-infected and -uninfected men and women. Med (Baltim). 2016;95(46):e5399. https:\/\/doi.org\/10.1097\/MD.0000000000005399.","journal-title":"Med (Baltim)"},{"issue":"2","key":"776_CR6","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1007\/s11904-020-00483-5","volume":"17","author":"SS Bailin","year":"2020","unstructured":"Bailin SS, Gabriel CL, Wanjalla CN, Koethe JR. Obesity and weight gain in persons with HIV. Curr HIV AIDS Rep. 2020;17(2):138\u201350. https:\/\/doi.org\/10.1007\/s11904-020-00483-5.","journal-title":"Curr HIV AIDS Rep"},{"issue":"1","key":"776_CR7","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1056\/NEJMoa1614362","volume":"377","author":"GBDO Collaborators","year":"2017","unstructured":"Collaborators GBDO, Afshin A, Forouzanfar MH, Reitsma MB, Sur P, Estep K, et al. Health effects of overweight and obesity in 195 countries over 25 years. N Engl J Med. 2017;377(1):13\u201327. https:\/\/doi.org\/10.1056\/NEJMoa1614362.","journal-title":"N Engl J Med"},{"issue":"1","key":"776_CR8","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1089\/aid.2015.0147","volume":"32","author":"JR Koethe","year":"2016","unstructured":"Koethe JR, Jenkins CA, Lau B, Shepherd BE, Justice AC, Tate JP, et al. Rising obesity prevalence and weight gain among adults starting antiretroviral therapy in the United States and Canada. AIDS Res Hum Retroviruses. 2016;32(1):50\u20138. https:\/\/doi.org\/10.1089\/aid.2015.0147.","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"6","key":"776_CR9","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.diabet.2019.02.008","volume":"45","author":"JP Bastard","year":"2019","unstructured":"Bastard JP, Couffignal C, Fellahi S, Bard JM, Mentre F, Salmon D, et al. Diabetes and dyslipidaemia are associated with oxidative stress independently of inflammation in long-term antiretroviral-treated HIV-infected patients. Diabetes Metab. 2019;45(6):573\u201381. https:\/\/doi.org\/10.1016\/j.diabet.2019.02.008.","journal-title":"Diabetes Metab"},{"issue":"1","key":"776_CR10","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/s41572-020-0181-1","volume":"6","author":"JR Koethe","year":"2020","unstructured":"Koethe JR, Lagathu C, Lake JE, Domingo P, Calmy A, Falutz J, et al. HIV and antiretroviral therapy-related fat alterations. Nat Rev Dis Primers. 2020;6(1):48. https:\/\/doi.org\/10.1038\/s41572-020-0181-1.","journal-title":"Nat Rev Dis Primers"},{"issue":"4","key":"776_CR11","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1007\/s10461-019-02645-y","volume":"24","author":"E Panza","year":"2020","unstructured":"Panza E, Wing EJ, Wing R. Behavioral weight loss: a promising treatment for obesity in adults with HIV. AIDS Behav. 2020;24(4):1085\u201391. https:\/\/doi.org\/10.1007\/s10461-019-02645-y.","journal-title":"AIDS Behav"},{"issue":"Suppl 4","key":"776_CR12","doi-asserted-by":"publisher","first-page":"e13256","DOI":"10.1111\/obr.13256","volume":"22","author":"A Bellicha","year":"2021","unstructured":"Bellicha A, van Baak MA, Battista F, Beaulieu K, Blundell JE, Busetto L, et al. Effect of exercise training on weight loss, body composition changes, and weight maintenance in adults with overweight or obesity: an overview of 12 systematic reviews and 149 studies. Obes Rev. 2021;22(Suppl 4):e13256. https:\/\/doi.org\/10.1111\/obr.13256.","journal-title":"Obes Rev"},{"key":"776_CR13","doi-asserted-by":"publisher","first-page":"37","DOI":"10.2147\/DMSO.S89836","volume":"9","author":"L Montesi","year":"2016","unstructured":"Montesi L, El Ghoch M, Brodosi L, Calugi S, Marchesini G, Dalle Grave R. Long-term weight loss maintenance for obesity: a multidisciplinary approach. Diabetes Metab Syndr Obes. 2016;9:37\u201346. https:\/\/doi.org\/10.2147\/DMSO.S89836.","journal-title":"Diabetes Metab Syndr Obes"},{"issue":"3","key":"776_CR14","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1093\/cid\/ciae449","volume":"80","author":"D Anderson","year":"2025","unstructured":"Anderson D, Ramgopal M, Hagins DP, Lee J, Simonson RB, Hsu TH, et al. DEFINE: a prospective, randomized, phase 4 trial to assess a protease inhibitor-based regimen switch strategy to manage integrase inhibitor-related weight gain. Clin Infect Dis. 2025;80(3):602\u201312. https:\/\/doi.org\/10.1093\/cid\/ciae449.","journal-title":"Clin Infect Dis"},{"issue":"8","key":"776_CR15","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1093\/cid\/ciz1243","volume":"71","author":"J van Wyk","year":"2020","unstructured":"van Wyk J, Ajana F, Bisshop F, De Wit S, Osiyemi O, Portilla Sogorb J, et al. Efficacy and safety of switching to Dolutegravir\/Lamivudine fixed-dose 2-drug regimen vs continuing a Tenofovir Alafenamide-based 3- or 4-drug regimen for maintenance of virologic suppression in adults living with human immunodeficiency virus type 1: phase 3, randomized, noninferiority TANGO study. Clin Infect Dis. 2020;71(8):1920\u20139. https:\/\/doi.org\/10.1093\/cid\/ciz1243.","journal-title":"Clin Infect Dis"},{"issue":"4","key":"776_CR16","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1093\/cid\/ciac130","volume":"76","author":"JM Llibre","year":"2023","unstructured":"Llibre JM, Brites C, Cheng CY, Osiyemi O, Galera C, Hocqueloux L, et al. Efficacy and safety of switching to the 2-drug regimen Dolutegravir\/Lamivudine versus continuing a 3- or 4-drug regimen for maintaining virologic suppression in adults living with human immunodeficiency virus 1 (HIV-1): week 48 results from the phase 3, noninferiority SALSA randomized trial. Clin Infect Dis. 2023;76(4):720\u20139. https:\/\/doi.org\/10.1093\/cid\/ciac130.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"776_CR17","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.tcm.2021.12.008","volume":"33","author":"AM Chao","year":"2023","unstructured":"Chao AM, Tronieri JS, Amaro A, Wadden TA. Semaglutide for the treatment of obesity. Trends Cardiovasc Med. 2023;33(3):159\u201366. https:\/\/doi.org\/10.1016\/j.tcm.2021.12.008.","journal-title":"Trends Cardiovasc Med"},{"issue":"10","key":"776_CR18","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1038\/s41366-023-01337-x","volume":"47","author":"YLL de Mesquita","year":"2023","unstructured":"de Mesquita YLL, Pera Calvi I, Reis Marques I, Almeida Cruz S, Padrao EMH, Carvalho PEP, et al. Efficacy and safety of the dual GIP and GLP-1 receptor agonist Tirzepatide for weight loss: a meta-analysis of randomized controlled trials. Int J Obes (Lond). 2023;47(10):883\u201392. https:\/\/doi.org\/10.1038\/s41366-023-01337-x.","journal-title":"Int J Obes (Lond)"},{"issue":"2","key":"776_CR19","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1210\/clinem\/dgaa863","volume":"106","author":"MK Thomas","year":"2021","unstructured":"Thomas MK, Nikooienejad A, Bray R, Cui X, Wilson J, Duffin K, et al. Dual GIP and GLP-1 receptor agonist tirzepatide improves beta-cell function and insulin sensitivity in type 2 diabetes. J Clin Endocrinol Metab. 2021;106(2):388\u201396. https:\/\/doi.org\/10.1210\/clinem\/dgaa863.","journal-title":"J Clin Endocrinol Metab"},{"issue":"10026","key":"776_CR20","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1016\/S0140-6736(16)30054-X","volume":"387","author":"NCDRF Collaboration","year":"2016","unstructured":"Collaboration NCDRF. Trends in adult body-mass index in 200 countries from 1975 to 2014: a pooled analysis of 1698 population-based measurement studies with 19.2 million participants. Lancet. 2016;387(10026):1377\u201396. https:\/\/doi.org\/10.1016\/S0140-6736(16)30054-X.","journal-title":"Lancet"},{"issue":"9765","key":"776_CR21","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/S0140-6736(10)62037-5","volume":"377","author":"MM Finucane","year":"2011","unstructured":"Finucane MM, Stevens GA, Cowan MJ, Danaei G, Lin JK, Paciorek CJ, et al. National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9.1\u00a0million participants. Lancet. 2011;377(9765):557\u201367. https:\/\/doi.org\/10.1016\/S0140-6736(10)62037-5.","journal-title":"Lancet"},{"key":"776_CR22","unstructured":"Fryar CDCM, Afful J. Prevalence of overweight, obesity, and severe obesity among adults aged 20 and over: united States, 1960\u20131962 through 2017\u20132018. NCHS Health E-Stats. MD, USA.2020."},{"issue":"7","key":"776_CR23","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.3851\/IMP2348","volume":"17","author":"T Tate","year":"2012","unstructured":"Tate T, Willig AL, Willig JH, Raper JL, Moneyham L, Kempf MC, et al. HIV infection and obesity: where did all the wasting go? Antivir Ther. 2012;17(7):1281\u20139. https:\/\/doi.org\/10.3851\/IMP2348.","journal-title":"Antivir Ther"},{"issue":"13","key":"776_CR24","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1097\/01.aids.0000181011.62385.91","volume":"19","author":"TT Brown","year":"2005","unstructured":"Brown TT, Li X, Cole SR, Kingsley LA, Palella FJ, Riddler SA, et al. Cumulative exposure to nucleoside analogue reverse transcriptase inhibitors is associated with insulin resistance markers in the Multicenter AIDS Cohort Study. AIDS. 2005;19(13):1375\u201383. https:\/\/doi.org\/10.1097\/01.aids.0000181011.62385.91.","journal-title":"AIDS"},{"issue":"8","key":"776_CR25","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1093\/cid\/ciab444","volume":"73","author":"KM Erlandson","year":"2021","unstructured":"Erlandson KM, Carter CC, Melbourne K, Brown TT, Cohen C, Das M, et al. Weight change following antiretroviral therapy switch in people with viral suppression: pooled data from randomized clinical trials. Clin Infect Dis. 2021;73(8):1440\u201351. https:\/\/doi.org\/10.1093\/cid\/ciab444.","journal-title":"Clin Infect Dis"},{"issue":"9","key":"776_CR26","doi-asserted-by":"publisher","first-page":"e471","DOI":"10.1093\/cid\/ciaa177","volume":"71","author":"JE Lake","year":"2020","unstructured":"Lake JE, Wu K, Bares SH, Debroy P, Godfrey C, Koethe JR, et al. Risk factors for weight gain following switch to integrase inhibitor-based antiretroviral therapy. Clin Infect Dis. 2020;71(9):e471\u20137. https:\/\/doi.org\/10.1093\/cid\/ciaa177.","journal-title":"Clin Infect Dis"},{"issue":"27","key":"776_CR27","doi-asserted-by":"publisher","first-page":"e1081","DOI":"10.1097\/MD.0000000000001081","volume":"94","author":"AM Thompson-Paul","year":"2015","unstructured":"Thompson-Paul AM, Wei SC, Mattson CL, Robertson M, Hernandez-Romieu AC, Bell TK, et al. Obesity Among HIV-Infected Adults Receiving Medical Care in the United States: Data From the Cross-Sectional Medical Monitoring Project and National Health and Nutrition Examination Survey. Med (Baltim). 2015;94(27):e1081. https:\/\/doi.org\/10.1097\/MD.0000000000001081.","journal-title":"Med (Baltim)."},{"issue":"9","key":"776_CR28","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1089\/AID.2015.0062","volume":"31","author":"AL Willig","year":"2015","unstructured":"Willig AL, Westfall AO, Overton ET, Mugavero MJ, Burkholder GA, Kim D, et al. Obesity is associated with race\/sex disparities in diabetes and hypertension prevalence, but not cardiovascular disease, among HIV-infected adults. AIDS Res Hum Retroviruses. 2015;31(9):898\u2013904. https:\/\/doi.org\/10.1089\/AID.2015.0062.","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"11","key":"776_CR29","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1093\/cid\/ciad404","volume":"77","author":"L Zino","year":"2023","unstructured":"Zino L, Wit F, Rokx C, den Hollander JG, van der Valk M, Richel O, et al. Outcomes of bariatric surgery in people with human immunodeficiency virus: a retrospective analysis from the ATHENA cohort. Clin Infect Dis. 2023;77(11):1561\u20138. https:\/\/doi.org\/10.1093\/cid\/ciad404.","journal-title":"Clin Infect Dis"},{"issue":"4","key":"776_CR30","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1007\/s15010-023-02009-8","volume":"51","author":"L Mavarani","year":"2023","unstructured":"Mavarani L, Albayrak-Rena S, Potthoff A, Hower M, Dolff S, Sammet S, et al. Changes in body mass index, weight, and waist-to-hip ratio over five years in HIV-positive individuals in the HIV heart aging study compared to the general population. Infection. 2023;51(4):1081\u201391. https:\/\/doi.org\/10.1007\/s15010-023-02009-8.","journal-title":"Infection"},{"issue":"9","key":"776_CR31","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1056\/NEJMoa1506816","volume":"373","author":"ISS Group","year":"2015","unstructured":"Group ISS, Lundgren JD, Babiker AG, Gordin F, Emery S, Grund B, et al. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med. 2015;373(9):795\u2013807. https:\/\/doi.org\/10.1056\/NEJMoa1506816.","journal-title":"N Engl J Med"},{"issue":"11","key":"776_CR32","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1016\/S1473-3099(13)70271-8","volume":"13","author":"JE Lake","year":"2013","unstructured":"Lake JE, Currier JS. Metabolic disease in HIV infection. Lancet Infect Dis. 2013;13(11):964\u201375. https:\/\/doi.org\/10.1016\/S1473-3099(13)70271-8.","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"776_CR33","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1038\/s41580-018-0093-z","volume":"20","author":"AL Ghaben","year":"2019","unstructured":"Ghaben AL, Scherer PE. Adipogenesis and metabolic health. Nat Rev Mol Cell Biol. 2019;20(4):242\u201358. https:\/\/doi.org\/10.1038\/s41580-018-0093-z.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"776_CR34","doi-asserted-by":"publisher","first-page":"101116","DOI":"10.1016\/j.eclinm.2021.101116","volume":"40","author":"J Bischoff","year":"2021","unstructured":"Bischoff J, Gu W, Schwarze-Zander C, Boesecke C, Wasmuth JC, van Bremen K, et al. Stratifying the risk of NAFLD in patients with HIV under combination antiretroviral therapy (cART). EClinicalMedicine. 2021;40:101116. https:\/\/doi.org\/10.1016\/j.eclinm.2021.101116.","journal-title":"EClinicalMedicine"},{"issue":"3","key":"776_CR35","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1097\/EDE.0000000000000815","volume":"29","author":"JR Nansseu","year":"2018","unstructured":"Nansseu JR, Bigna JJ, Kaze AD, Noubiap JJ. Incidence and risk factors for prediabetes and diabetes mellitus among HIV-infected adults on antiretroviral therapy: a systematic review and meta-analysis. Epidemiology. 2018;29(3):431\u201341. https:\/\/doi.org\/10.1097\/EDE.0000000000000815.","journal-title":"Epidemiology"},{"issue":"1","key":"776_CR36","doi-asserted-by":"publisher","first-page":"e35","DOI":"10.1016\/S2468-2667(16)30020-2","volume":"2","author":"S Croxford","year":"2017","unstructured":"Croxford S, Kitching A, Desai S, Kall M, Edelstein M, Skingsley A, et al. Mortality and causes of death in people diagnosed with HIV in the era of highly active antiretroviral therapy compared with the general population: an analysis of a national observational cohort. Lancet Public Health. 2017;2(1):e35\u201346. https:\/\/doi.org\/10.1016\/S2468-2667(16)30020-2.","journal-title":"Lancet Public Health"},{"issue":"5","key":"776_CR37","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s11904-016-0330-z","volume":"13","author":"AL Willig","year":"2016","unstructured":"Willig AL, Overton ET. Metabolic complications and glucose metabolism in HIV infection: a review of the evidence. Curr HIV AIDS Rep. 2016;13(5):289\u201396. https:\/\/doi.org\/10.1007\/s11904-016-0330-z.","journal-title":"Curr HIV AIDS Rep"},{"issue":"4","key":"776_CR38","first-page":"676","volume":"22","author":"SK Grinspoon","year":"2014","unstructured":"Grinspoon SK. Cardiovascular disease in HIV: traditional and nontraditional risk factors. Top Antivir Med. 2014;22(4):676\u20139.","journal-title":"Top Antivir Med"},{"issue":"5","key":"776_CR39","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1097\/QAI.0000000000001722","volume":"78","author":"AC Achhra","year":"2018","unstructured":"Achhra AC, Sabin C, Ryom L, Hatleberg C, Antonella d\u2019Aminio M, de Wit S, et al. Body mass index and the risk of serious Non-AIDS events and All-Cause mortality in treated HIV-Positive individuals: D: A: D cohort analysis. J Acquir Immune Defic Syndr. 2018;78(5):579\u201388. https:\/\/doi.org\/10.1097\/QAI.0000000000001722.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"4","key":"776_CR40","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1038\/s41366-018-0210-2","volume":"43","author":"T Lung","year":"2019","unstructured":"Lung T, Jan S, Tan EJ, Killedar A, Hayes A. Impact of overweight, obesity and severe obesity on life expectancy of Australian adults. Int J Obes (Lond). 2019;43(4):782\u20139. https:\/\/doi.org\/10.1038\/s41366-018-0210-2.","journal-title":"Int J Obes (Lond)"},{"issue":"8","key":"776_CR41","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1001\/jamainternmed.2013.3728","volume":"173","author":"MS Freiberg","year":"2013","unstructured":"Freiberg MS, Chang CC, Kuller LH, Skanderson M, Lowy E, Kraemer KL, et al. HIV infection and the risk of acute myocardial infarction. JAMA Intern Med. 2013;173(8):614\u201322. https:\/\/doi.org\/10.1001\/jamainternmed.2013.3728.","journal-title":"JAMA Intern Med"},{"issue":"11","key":"776_CR42","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1097\/QAD.0000000000001496","volume":"31","author":"O Putcharoen","year":"2017","unstructured":"Putcharoen O, Wattanachanya L, Sophonphan J, Siwamogsatham S, Sapsirisavat V, Gatechompol S, et al. New-onset diabetes in HIV-treated adults: predictors, long-term renal and cardiovascular outcomes. AIDS. 2017;31(11):1535\u201343. https:\/\/doi.org\/10.1097\/QAD.0000000000001496.","journal-title":"AIDS"},{"issue":"1","key":"776_CR43","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s12981-020-00266-3","volume":"17","author":"JE Heron","year":"2020","unstructured":"Heron JE, Bagnis CI, Gracey DM. Contemporary issues and new challenges in chronic kidney disease amongst people living with HIV. AIDS Res Ther. 2020;17(1):11. https:\/\/doi.org\/10.1186\/s12981-020-00266-3.","journal-title":"AIDS Res Ther"},{"issue":"2","key":"776_CR44","doi-asserted-by":"publisher","first-page":"e98","DOI":"10.1161\/CIR.0000000000000695","volume":"140","author":"MJ Feinstein","year":"2019","unstructured":"Feinstein MJ, Hsue PY, Benjamin LA, Bloomfield GS, Currier JS, Freiberg MS, et al. Characteristics, prevention, and management of cardiovascular disease in people living with HIV: a scientific statement from the American Heart Association. Circulation. 2019;140(2):e98\u2013124. https:\/\/doi.org\/10.1161\/CIR.0000000000000695.","journal-title":"Circulation"},{"issue":"4","key":"776_CR45","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1111\/hiv.12294","volume":"17","author":"AC Achhra","year":"2016","unstructured":"Achhra AC, Mocroft A, Reiss P, Sabin C, Ryom L, de Wit S, et al. Short-term weight gain after antiretroviral therapy initiation and subsequent risk of cardiovascular disease and diabetes: the D:A:D study. HIV Med. 2016;17(4):255\u201368. https:\/\/doi.org\/10.1111\/hiv.12294.","journal-title":"HIV Med"},{"issue":"9","key":"776_CR46","doi-asserted-by":"publisher","first-page":"101783","DOI":"10.1016\/j.cpcardiol.2023.101783","volume":"48","author":"A Avagimyan","year":"2023","unstructured":"Avagimyan A, Pogosova N, Kakturskiy L, Sheibani M, Urazova O, Trofimenko A, et al. HIV-Related atherosclerosis: State-of-the-Art-Review. Curr Probl Cardiol. 2023;48(9):101783. https:\/\/doi.org\/10.1016\/j.cpcardiol.2023.101783.","journal-title":"Curr Probl Cardiol"},{"issue":"2","key":"776_CR47","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1210\/endrev\/bnad028","volume":"45","author":"CE Ramirez Bustamante","year":"2024","unstructured":"Ramirez Bustamante CE, Agarwal N, Cox AR, Hartig SM, Lake JE, Balasubramanyam A. Adipose tissue dysfunction and energy balance paradigms in people living with HIV. Endocr Rev. 2024;45(2):190\u2013209. https:\/\/doi.org\/10.1210\/endrev\/bnad028.","journal-title":"Endocr Rev"},{"issue":"1","key":"776_CR48","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1097\/01.qai.0000233310.90484.16","volume":"43","author":"FJ Palella Jr.","year":"2006","unstructured":"Palella FJ Jr., Baker RK, Moorman AC, Chmiel JS, Wood KC, Brooks JT, et al. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr. 2006;43(1):27\u201334. https:\/\/doi.org\/10.1097\/01.qai.0000233310.90484.16.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"4","key":"776_CR49","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1111\/j.1468-1293.2012.01051.x","volume":"14","author":"R Weber","year":"2013","unstructured":"Weber R, Ruppik M, Rickenbach M, Spoerri A, Furrer H, Battegay M, et al. Decreasing mortality and changing patterns of causes of death in the Swiss HIV Cohort Study. HIV Med. 2013;14(4):195\u2013207. https:\/\/doi.org\/10.1111\/j.1468-1293.2012.01051.x.","journal-title":"HIV Med"},{"key":"776_CR50","unstructured":"Diagnoses HIV. Deaths, and Prevalence. https:\/\/www.cdc.gov\/hiv-data\/nhss\/hiv-diagnoses-deaths-prevalence.html (2025). Accessed\u00a02 Oct 2025."},{"issue":"1","key":"776_CR51","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1097\/QAI.0000000000001014","volume":"73","author":"JL Marcus","year":"2016","unstructured":"Marcus JL, Chao CR, Leyden WA, Xu L, Quesenberry CP Jr., Klein DB, et al. Narrowing the gap in life expectancy between HIV-infected and HIV-uninfected individuals with access to care. J Acquir Immune Defic Syndr. 2016;73(1):39\u201346. https:\/\/doi.org\/10.1097\/QAI.0000000000001014.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"1","key":"776_CR52","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1590\/1806-9282.66.1.67","volume":"66","author":"LR Soares","year":"2020","unstructured":"Soares LR, Menezes GC, Barreto APM, Sant\u2019Anna MSL, Cardoso NMA, Casseb J, et al. Association between changes in body fat distribution, biochemical profile, time of HIV diagnosis, and antiretroviral treatment in adults living with and without virus infection. Rev Assoc Med Bras (1992). 2020;66(1):67\u201373. https:\/\/doi.org\/10.1590\/1806-9282.66.1.67.","journal-title":"Rev Assoc Med Bras (1992)"},{"key":"776_CR53","doi-asserted-by":"publisher","unstructured":"Baarts RB, Jensen MR, Hansen OM, Haddock B, Prescott E, Hovind P, et al. Age\u2010 and sex\u2010specific changes in visceral fat mass throughout the life\u2010span. Obesity. 2023;31(7):1953\u201361. https:\/\/doi.org\/10.1002\/oby.23779.","DOI":"10.1002\/oby.23779"},{"issue":"1","key":"776_CR54","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1210\/clinem\/dgae369","volume":"110","author":"SS Bailin","year":"2024","unstructured":"Bailin SS, Gabriel CL, Gangula RD, Hannah L, Nair S, Carr JJ, et al. Single-cell analysis of subcutaneous fat reveals profibrotic cells that correlate with visceral adiposity in HIV. J Clin Endocrinol Metab. 2024;110(1):238\u201353. https:\/\/doi.org\/10.1210\/clinem\/dgae369.","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"776_CR55","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1097\/QAD.0000000000002168","volume":"33","author":"J Gorwood","year":"2019","unstructured":"Gorwood J, Bourgeois C, Mantecon M, Atlan M, Pourcher V, Pourcher G, et al. Impact of HIV\/simian immunodeficiency virus infection and viral proteins on adipose tissue fibrosis and adipogenesis. AIDS. 2019;33(6):953\u201364. https:\/\/doi.org\/10.1097\/QAD.0000000000002168.","journal-title":"AIDS"},{"issue":"4","key":"776_CR56","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1177\/135965350400900412","volume":"9","author":"V Jan","year":"2004","unstructured":"Jan V, Cervera P, Maachi M, Baudrimont M, Kim M, Vidal H, et al. Altered fat differentiation and adipocytokine expression are inter-related and linked to morphological changes and insulin resistance in HIV-1-infected lipodystrophic patients. Antivir Ther. 2004;9(4):555\u201364.","journal-title":"Antivir Ther"},{"issue":"1","key":"776_CR57","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1161\/CIRCULATIONAHA.106.675355","volume":"116","author":"CS Fox","year":"2007","unstructured":"Fox CS, Massaro JM, Hoffmann U, Pou KM, Maurovich-Horvat P, Liu CY, et al. Abdominal visceral and subcutaneous adipose tissue compartments: association with metabolic risk factors in the Framingham Heart Study. Circulation. 2007;116(1):39\u201348. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.106.675355.","journal-title":"Circulation"},{"issue":"3","key":"776_CR58","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1097\/qai.0b013e31814b94e2","volume":"46","author":"C Grunfeld","year":"2007","unstructured":"Grunfeld C, Rimland D, Gibert CL, Powderly WG, Sidney S, Shlipak MG, et al. Association of upper trunk and visceral adipose tissue volume with insulin resistance in control and HIV-infected subjects in the FRAM Study. JAIDS J Acquir Immune Defic Syndr. 2007;46(3):283\u201390. https:\/\/doi.org\/10.1097\/qai.0b013e31814b94e2.","journal-title":"JAIDS J Acquir Immune Defic Syndr"},{"issue":"10","key":"776_CR59","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1097\/QAD.0000000000003936","volume":"38","author":"RL Goldberg","year":"2024","unstructured":"Goldberg RL, Peterson TE, Haberlen SA, Witt MD, Palella FJ, Magnani JW, et al. Associations between epicardial, visceral, and subcutaneous adipose tissue with diastolic function in men with and without HIV. AIDS. 2024;38(10):1485\u201393. https:\/\/doi.org\/10.1097\/QAD.0000000000003936.","journal-title":"AIDS"},{"issue":"7","key":"776_CR60","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1016\/j.cgh.2023.01.001","volume":"21","author":"M Kalligeros","year":"2023","unstructured":"Kalligeros M, Vassilopoulos A, Shehadeh F, Vassilopoulos S, Lazaridou I, Mylonakis E, et al. Prevalence and characteristics of nonalcoholic fatty liver disease and fibrosis in people living with HIV monoinfection: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2023;21(7):1708\u201322. https:\/\/doi.org\/10.1016\/j.cgh.2023.01.001.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"13","key":"776_CR61","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1097\/QAD.0000000000001558","volume":"31","author":"KM Erlandson","year":"2017","unstructured":"Erlandson KM, Fiorillo S, Masawi F, Scherzinger A, McComsey GA, Lake JE, et al. Antiretroviral initiation is associated with increased skeletal muscle area and fat content. AIDS. 2017;31(13):1831\u20138. https:\/\/doi.org\/10.1097\/QAD.0000000000001558.","journal-title":"AIDS"},{"issue":"12","key":"776_CR62","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1111\/hiv.13539","volume":"24","author":"GL Ditzenberger","year":"2023","unstructured":"Ditzenberger GL, Oliveira VHF, Jankowski CM, Erlandson KM. The use of non-invasive imaging modalities for the assessment of skeletal muscle quantity and quality in people with HIV: a narrative review. HIV Med. 2023;24(12):1176\u201389. https:\/\/doi.org\/10.1111\/hiv.13539.","journal-title":"HIV Med"},{"issue":"1","key":"776_CR63","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/s41387-025-00381-y","volume":"15","author":"S Park","year":"2025","unstructured":"Park S, Widmer A, Swartz AZ, Koethe JR, Silver HJ. Density of ectopic fat depots predict distinct biomarkers of glycemic and insulinemic status in persons with HIV. Nutr Diabetes. 2025;15(1):28. https:\/\/doi.org\/10.1038\/s41387-025-00381-y.","journal-title":"Nutr Diabetes"},{"issue":"4","key":"776_CR64","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1097\/QAI.0000000000002776","volume":"88","author":"A Kousari","year":"2021","unstructured":"Kousari A, Moser C, Olefsky M, Brown TT, Currier JS, McComsey GA, et al. Poorer muscle quality and quantity with ART initiation is associated with greater inflammation and immune activation. J Acquir Immune Defic Syndr. 2021;88(4):399\u2013405. https:\/\/doi.org\/10.1097\/QAI.0000000000002776.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"2","key":"776_CR65","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1038\/s41576-021-00414-z","volume":"23","author":"RJF Loos","year":"2022","unstructured":"Loos RJF, Yeo GSH. The genetics of obesity: from discovery to biology. Nat Rev Genet. 2022;23(2):120\u201333. https:\/\/doi.org\/10.1038\/s41576-021-00414-z.","journal-title":"Nat Rev Genet"},{"key":"776_CR66","doi-asserted-by":"publisher","unstructured":"Bell CN, Kerr J, Young JL. Associations between Obesity, obesogenic Environments, and structural racism vary by County-Level Racial composition. Int J Environ Res Public Health. 2019;16(5). https:\/\/doi.org\/10.3390\/ijerph16050861.","DOI":"10.3390\/ijerph16050861"},{"issue":"1","key":"776_CR67","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1186\/s12889-022-13036-9","volume":"22","author":"N Becker","year":"2022","unstructured":"Becker N, Mkhonta A, Sibeko LN. The prevalence of overweight\/obesity and its association with household food insecurity among women living with HIV in rural Eswatini. BMC Public Health. 2022;22(1):629. https:\/\/doi.org\/10.1186\/s12889-022-13036-9.","journal-title":"BMC Public Health"},{"issue":"2","key":"776_CR68","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1080\/09540121.2017.1348597","volume":"30","author":"KP Derose","year":"2018","unstructured":"Derose KP, Rios-Castillo I, Fulcar MA, Payan DD, Palar K, Escala L, et al. Severe food insecurity is associated with overweight and increased body fat among people living with HIV in the Dominican Republic. AIDS Care. 2018;30(2):182\u201390. https:\/\/doi.org\/10.1080\/09540121.2017.1348597.","journal-title":"AIDS Care"},{"issue":"8","key":"776_CR69","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1038\/ijo.2015.59","volume":"39","author":"FL Greenway","year":"2015","unstructured":"Greenway FL. Physiological adaptations to weight loss and factors favouring weight regain. Int J Obes (Lond). 2015;39(8):1188\u201396. https:\/\/doi.org\/10.1038\/ijo.2015.59.","journal-title":"Int J Obes (Lond)"},{"key":"776_CR70","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1146\/annurev.nutr.21.1.323","volume":"21","author":"RR Wing","year":"2001","unstructured":"Wing RR, Hill JO. Successful weight loss maintenance. Annu Rev Nutr. 2001;21:323\u201341. https:\/\/doi.org\/10.1146\/annurev.nutr.21.1.323.","journal-title":"Annu Rev Nutr"},{"key":"776_CR71","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.ejim.2021.01.002","volume":"93","author":"L Busetto","year":"2021","unstructured":"Busetto L, Bettini S, Makaronidis J, Roberts CA, Halford JCG, Batterham RL. Mechanisms of weight regain. Eur J Intern Med. 2021;93:3\u20137. https:\/\/doi.org\/10.1016\/j.ejim.2021.01.002.","journal-title":"Eur J Intern Med"},{"issue":"17","key":"776_CR72","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1056\/NEJMoa1105816","volume":"365","author":"P Sumithran","year":"2011","unstructured":"Sumithran P, Prendergast LA, Delbridge E, Purcell K, Shulkes A, Kriketos A, et al. Long-term persistence of hormonal adaptations to weight loss. N Engl J Med. 2011;365(17):1597\u2013604. https:\/\/doi.org\/10.1056\/NEJMoa1105816.","journal-title":"N Engl J Med"},{"key":"776_CR73","doi-asserted-by":"publisher","unstructured":"Roh E, Choi KM. Hormonal Gut-Brain signaling for the treatment of obesity. Int J Mol Sci. 2023;24(4). https:\/\/doi.org\/10.3390\/ijms24043384.","DOI":"10.3390\/ijms24043384"},{"key":"776_CR74","doi-asserted-by":"publisher","first-page":"108824","DOI":"10.1016\/j.pharmthera.2025.108824","volume":"269","author":"A Arredouani","year":"2025","unstructured":"Arredouani A. GLP-1 receptor agonists, are we witnessing the emergence of a paradigm shift for neuro-cardio-metabolic disorders? Pharmacol Ther. 2025;269:108824. https:\/\/doi.org\/10.1016\/j.pharmthera.2025.108824.","journal-title":"Pharmacol Ther"},{"issue":"3","key":"776_CR75","doi-asserted-by":"publisher","first-page":"e0247307","DOI":"10.1371\/journal.pone.0247307","volume":"16","author":"ZJ Ward","year":"2021","unstructured":"Ward ZJ, Bleich SN, Long MW, Gortmaker SL. Association of body mass index with health care expenditures in the united States by age and sex. PLoS ONE. 2021;16(3):e0247307. https:\/\/doi.org\/10.1371\/journal.pone.0247307.","journal-title":"PLoS ONE"},{"issue":"9","key":"776_CR76","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1001\/jamainternmed.2024.2525","volume":"184","author":"PJ Rodriguez","year":"2024","unstructured":"Rodriguez PJ, Goodwin Cartwright BM, Gratzl S, Brar R, Baker C, Gluckman TJ, et al. Semaglutide vs tirzepatide for weight loss in adults with overweight or obesity. JAMA Intern Med. 2024;184(9):1056\u201364. https:\/\/doi.org\/10.1001\/jamainternmed.2024.2525.","journal-title":"JAMA Intern Med"},{"issue":"2","key":"776_CR77","doi-asserted-by":"publisher","first-page":"199","DOI":"10.7326\/ANNALS-24-01590","volume":"178","author":"A Moiz","year":"2025","unstructured":"Moiz A, Filion KB, Toutounchi H, Tsoukas MA, Yu OHY, Peters TM, et al. Efficacy and safety of glucagon-like peptide-1 receptor agonists for weight loss among adults without diabetes\u202f: A systematic review of randomized controlled trials. Ann Intern Med. 2025;178(2):199\u2013217. https:\/\/doi.org\/10.7326\/ANNALS-24-01590.","journal-title":"Ann Intern Med"},{"key":"776_CR78","unstructured":"Novo Nordisk. WEGOVY (semaglutide) [package insert]. U.S. Food and Drug Administration https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/215256s007lbl.pdf. Revised July 2023. Accessed 15 Sept 2025."},{"key":"776_CR79","unstructured":"Novo Nordisk. SAXENDA (liraglutide) [package insert]. U.S. Food and Drug Administration https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/206321s016lbl.pdf. Revised April 2023. Accessed 15 Sept 2025."},{"key":"776_CR80","unstructured":"Eli Lilly and Company. ZEPBOUND\u00ae (tirzepatide) [package insert]. U.S. Food and Drug Administration https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/217806s003lbl.pdf. Revised March 2024. Accessed 15 Sept 2025."},{"issue":"24","key":"776_CR81","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","volume":"389","author":"AM Lincoff","year":"2023","unstructured":"Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221\u201332. https:\/\/doi.org\/10.1056\/NEJMoa2307563.","journal-title":"N Engl J Med"},{"issue":"7","key":"776_CR82","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1038\/s41591-024-03015-5","volume":"30","author":"HM Colhoun","year":"2024","unstructured":"Colhoun HM, Lingvay I, Brown PM, Deanfield J, Brown-Frandsen K, Kahn SE, et al. Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial. Nat Med. 2024;30(7):2058\u201366. https:\/\/doi.org\/10.1038\/s41591-024-03015-5.","journal-title":"Nat Med"},{"issue":"1","key":"776_CR83","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1056\/NEJMoa2416394","volume":"393","author":"LJ Aronne","year":"2025","unstructured":"Aronne LJ, Horn DB, le Roux CW, Ho W, Falcon BL, Gomez Valderas E, et al. Tirzepatide as compared with semaglutide for the treatment of obesity. N Engl J Med. 2025;393(1):26\u201336. https:\/\/doi.org\/10.1056\/NEJMoa2416394.","journal-title":"N Engl J Med"},{"issue":"13","key":"776_CR84","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1056\/NEJMoa2404881","volume":"391","author":"A Malhotra","year":"2024","unstructured":"Malhotra A, Grunstein RR, Fietze I, Weaver TE, Redline S, Azarbarzin A, et al. Tirzepatide for the treatment of obstructive sleep apnea and obesity. N Engl J Med. 2024;391(13):1193\u2013205. https:\/\/doi.org\/10.1056\/NEJMoa2404881.","journal-title":"N Engl J Med"},{"issue":"8","key":"776_CR85","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/s2213-8587(24)00150-5","volume":"12","author":"AR Eckard","year":"2024","unstructured":"Eckard AR, Wu Q, Sattar A, Ansari-Gilani K, Labbato D, Foster T, et al. Once-weekly semaglutide in people with HIV-associated lipohypertrophy: a randomised, double-blind, placebo-controlled phase 2b single-centre clinical trial. Lancet Diabetes Endocrinol. 2024;12(8):523\u201334. https:\/\/doi.org\/10.1016\/s2213-8587(24)00150-5.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"776_CR86","doi-asserted-by":"publisher","first-page":"835","DOI":"10.7326\/M23-3354","volume":"177","author":"JE Lake","year":"2024","unstructured":"Lake JE, Kitch DW, Kantor A, Muthupillai R, Klingman KL, Vernon C, et al. The effect of open-label semaglutide on metabolic dysfunction-associated steatotic liver disease in people with HIV. Ann Intern Med. 2024;177(6):835\u20138. https:\/\/doi.org\/10.7326\/M23-3354.","journal-title":"Ann Intern Med"},{"issue":"4","key":"776_CR87","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1097\/QAD.0000000000003791","volume":"38","author":"L Haidar","year":"2024","unstructured":"Haidar L, Crane HM, Nance RM, Webel A, Ruderman SA, Whitney BM, et al. Weight loss associated with semaglutide treatment among people with HIV. AIDS. 2024;38(4):531\u20135. https:\/\/doi.org\/10.1097\/QAD.0000000000003791.","journal-title":"AIDS"},{"issue":"4","key":"776_CR88","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1093\/cid\/ciae151","volume":"79","author":"Q Nguyen","year":"2024","unstructured":"Nguyen Q, Wooten D, Lee D, Moreno M, Promer K, Rajagopal A, et al. Glucagon-like peptide 1 receptor agonists promote weight loss among people with HIV. Clin Infect Dis. 2024;79(4):978\u201382. https:\/\/doi.org\/10.1093\/cid\/ciae151.","journal-title":"Clin Infect Dis"},{"issue":"4","key":"776_CR89","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1111\/dom.15728","volume":"26","author":"IJ Neeland","year":"2024","unstructured":"Neeland IJ, Linge J, Birkenfeld AL. Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies. Diabetes Obes Metab. 2024;26(4):16\u201327. https:\/\/doi.org\/10.1111\/dom.15728.","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"776_CR90","doi-asserted-by":"publisher","first-page":"247","DOI":"10.3803\/EnM.2019.34.3.247","volume":"34","author":"JA Sargeant","year":"2019","unstructured":"Sargeant JA, Henson J, King JA, Yates T, Khunti K, Davies MJ. A review of the effects of Glucagon-Like Peptide-1 receptor agonists and Sodium-Glucose cotransporter 2 inhibitors on lean body mass in humans. Endocrinol Metab (Seoul). 2019;34(3):247\u201362. https:\/\/doi.org\/10.3803\/EnM.2019.34.3.247.","journal-title":"Endocrinol Metab (Seoul)"},{"issue":"3","key":"776_CR91","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/s11904-014-0215-y","volume":"11","author":"KM Erlandson","year":"2014","unstructured":"Erlandson KM, Schrack JA, Jankowski CM, Brown TT, Campbell TB. Functional impairment, disability, and frailty in adults aging with HIV-infection. Curr HIV AIDS Rep. 2014;11(3):279\u201390. https:\/\/doi.org\/10.1007\/s11904-014-0215-y.","journal-title":"Curr HIV AIDS Rep"},{"issue":"2","key":"776_CR92","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1093\/cid\/ciae384","volume":"80","author":"GL Ditzenberger","year":"2025","unstructured":"Ditzenberger GL, Lake JE, Kitch DW, Kantor A, Muthupillai R, Moser C, et al. Effects of semaglutide on muscle structure and function in the SLIM LIVER study. Clin Infect Dis. 2025;80(2):389\u201396. https:\/\/doi.org\/10.1093\/cid\/ciae384.","journal-title":"Clin Infect Dis"},{"issue":"4","key":"776_CR93","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1111\/hiv.13760","volume":"26","author":"N Nazarenko","year":"2025","unstructured":"Nazarenko N, Chen YY, Borkowski P, Biavati L, Parker M, Vargas-Pena C, et al. Weight and mortality in people living with HIV and heart failure: obesity paradox in the era of glucagon-like peptide 1 (GLP-1) receptor agonists and sodium-glucose cotransporter-2 (SGLT-2) inhibitors. HIV Med. 2025;26(4):581\u201391. https:\/\/doi.org\/10.1111\/hiv.13760.","journal-title":"HIV Med"},{"issue":"3","key":"776_CR94","doi-asserted-by":"publisher","first-page":"467","DOI":"10.2337\/cd23-0023","volume":"41","author":"HP Whitley","year":"2023","unstructured":"Whitley HP, Trujillo JM, Neumiller JJ. Special report: potential strategies for addressing GLP-1 and dual GLP-1\/GIP receptor agonist shortages. Clin Diabetes. 2023;41(3):467\u201373. https:\/\/doi.org\/10.2337\/cd23-0023.","journal-title":"Clin Diabetes"},{"issue":"8","key":"776_CR95","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1111\/dom.14725","volume":"24","author":"JPH Wilding","year":"2022","unstructured":"Wilding JPH, Batterham RL, Davies M, Van Gaal LF, Kandler K, Konakli K, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553\u201364. https:\/\/doi.org\/10.1111\/dom.14725.","journal-title":"Diabetes Obes Metab"},{"key":"776_CR96","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14113791","author":"M Quarenghi","year":"2025","unstructured":"Quarenghi M, Capelli S, Galligani G, Giana A, Preatoni G, Turri Quarenghi R. Weight regain after liraglutide, semaglutide or tirzepatide interruption: a narrative review of randomized studies. J Clin Med. 2025. https:\/\/doi.org\/10.3390\/jcm14113791.","journal-title":"J Clin Med"},{"issue":"1","key":"776_CR97","doi-asserted-by":"publisher","first-page":"e2457349","DOI":"10.1001\/jamanetworkopen.2024.57349","volume":"8","author":"PJ Rodriguez","year":"2025","unstructured":"Rodriguez PJ, Zhang V, Gratzl S, Do D, Goodwin Cartwright B, Baker C, et al. Discontinuation and reinitiation of Dual-Labeled GLP-1 receptor agonists among US adults with overweight or obesity. JAMA Netw Open. 2025;8(1):e2457349. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.57349.","journal-title":"JAMA Netw Open"},{"issue":"3","key":"776_CR98","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1097\/QAI.0b013e3181cbdaff","volume":"53","author":"J Falutz","year":"2010","unstructured":"Falutz J, Potvin D, Mamputu JC, Assaad H, Zoltowska M, Michaud SE, et al. Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension. J Acquir Immune Defic Syndr. 2010;53(3):311\u201322. https:\/\/doi.org\/10.1097\/QAI.0b013e3181cbdaff.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"3","key":"776_CR99","doi-asserted-by":"publisher","first-page":"154","DOI":"10.14283\/jfa.2018.45","volume":"8","author":"S Adrian","year":"2019","unstructured":"Adrian S, Scherzinger A, Sanyal A, Lake JE, Falutz J, Dube MP, et al. The growth hormone releasing hormone analogue, Tesamorelin, decreases muscle fat and increases muscle area in adults with HIV. J Frailty Aging. 2019;8(3):154\u20139. https:\/\/doi.org\/10.14283\/jfa.2018.45.","journal-title":"J Frailty Aging"},{"issue":"12","key":"776_CR100","doi-asserted-by":"publisher","first-page":"e821","DOI":"10.1016\/S2352-3018(19)30338-8","volume":"6","author":"TL Stanley","year":"2019","unstructured":"Stanley TL, Fourman LT, Feldpausch MN, Purdy J, Zheng I, Pan CS, et al. Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial. Lancet HIV. 2019;6(12):e821\u201330. https:\/\/doi.org\/10.1016\/S2352-3018(19)30338-8.","journal-title":"Lancet HIV"},{"key":"776_CR101","unstructured":"Theratechnologies. July. EGRIFTA SV\u2122 (tesamorelin for injection) [package insert]. U.S. Food and Drug Administration https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/022505s012s013lbl.pdf. Revised 2019. Accessed 15 Sept 2025."},{"issue":"14","key":"776_CR102","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1097\/QAD.0b013e32830a5058","volume":"22","author":"J Falutz","year":"2008","unstructured":"Falutz J, Allas S, Mamputu JC, Potvin D, Kotler D, Somero M, et al. Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation. AIDS. 2008;22(14):1719\u201328. https:\/\/doi.org\/10.1097\/QAD.0b013e32830a5058.","journal-title":"AIDS"},{"issue":"2","key":"776_CR103","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.ghir.2014.12.005","volume":"25","author":"TL Stanley","year":"2015","unstructured":"Stanley TL, Grinspoon SK. Effects of growth hormone-releasing hormone on visceral fat, metabolic, and cardiovascular indices in human studies. Growth Horm IGF Res. 2015;25(2):59\u201365. https:\/\/doi.org\/10.1016\/j.ghir.2014.12.005.","journal-title":"Growth Horm IGF Res"},{"issue":"10","key":"776_CR104","doi-asserted-by":"publisher","first-page":"e666","DOI":"10.1016\/S2352-3018(20)30241-1","volume":"7","author":"WDF Venter","year":"2020","unstructured":"Venter WDF, Sokhela S, Simmons B, Moorhouse M, Fairlie L, Mashabane N, et al. Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial. Lancet HIV. 2020;7(10):e666\u201376. https:\/\/doi.org\/10.1016\/S2352-3018(20)30241-1.","journal-title":"Lancet HIV"},{"issue":"3","key":"776_CR105","doi-asserted-by":"publisher","first-page":"ofae007","DOI":"10.1093\/ofid\/ofae007","volume":"11","author":"S Sokhela","year":"2024","unstructured":"Sokhela S, Venter WDF, Bosch B, Woods J, McCann K, Akpomiemie G, et al. Final 192-Week efficacy and safety results of the ADVANCE Trial, comparing 3 First-line antiretroviral regimens. Open Forum Infect Dis. 2024;11(3):ofae007. https:\/\/doi.org\/10.1093\/ofid\/ofae007.","journal-title":"Open Forum Infect Dis"},{"issue":"11","key":"776_CR106","doi-asserted-by":"publisher","first-page":"e3902","DOI":"10.1093\/cid\/ciaa1073","volume":"73","author":"R Griesel","year":"2021","unstructured":"Griesel R, Maartens G, Chirehwa M, Sokhela S, Akpomiemie G, Moorhouse M, et al. CYP2B6 genotype and weight gain differences between dolutegravir and efavirenz. Clin Infect Dis. 2021;73(11):e3902\u20139.","journal-title":"Clin Infect Dis"},{"issue":"27","key":"776_CR107","doi-asserted-by":"publisher","first-page":"2587","DOI":"10.1056\/NEJMoa1011205","volume":"363","author":"RM Grant","year":"2010","unstructured":"Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587\u201399. https:\/\/doi.org\/10.1056\/NEJMoa1011205.","journal-title":"N Engl J Med"},{"issue":"3","key":"776_CR108","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1093\/cid\/ciy083","volume":"67","author":"DV Glidden","year":"2018","unstructured":"Glidden DV, Mulligan K, McMahan V, Anderson PL, Guanira J, Chariyalertsak S, et al. Metabolic effects of preexposure prophylaxis with coformulated tenofovir disoproxil fumarate and emtricitabine. Clin Infect Dis. 2018;67(3):411\u20139. https:\/\/doi.org\/10.1093\/cid\/ciy083.","journal-title":"Clin Infect Dis"},{"issue":"7","key":"776_CR109","doi-asserted-by":"publisher","first-page":"e397","DOI":"10.1016\/S2352-3018(21)00071-0","volume":"8","author":"O Ogbuagu","year":"2021","unstructured":"Ogbuagu O, Ruane PJ, Podzamczer D, Salazar LC, Henry K, Asmuth DM, et al. Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet HIV. 2021;8(7):e397\u2013407. https:\/\/doi.org\/10.1016\/S2352-3018(21)00071-0.","journal-title":"Lancet HIV"},{"issue":"Supplement_1","key":"776_CR110","doi-asserted-by":"publisher","first-page":"S533","DOI":"10.1093\/ofid\/ofab466.1077","volume":"8","author":"S Shah","year":"2021","unstructured":"Shah S, Pilkington V, Hill A. 882. Use of tenofovir disoproxil fumarate shows weight loss vs placebo: a meta-analysis of 7 clinical trials in 19,359 HIV-negative individuals. Open Forum Infect Dis. 2021;8(Supplement_1):S533-S. https:\/\/doi.org\/10.1093\/ofid\/ofab466.1077.","journal-title":"Open Forum Infect Dis"},{"issue":"4","key":"776_CR111","doi-asserted-by":"publisher","first-page":"e25484","DOI":"10.1002\/jia2.25484","volume":"23","author":"K Bourgi","year":"2020","unstructured":"Bourgi K, Jenkins CA, Rebeiro PF, Palella F, Moore RD, Altoff KN, et al. Weight gain among treatment-na\u00efve persons with HIV starting integrase inhibitors compared to non-nucleoside reverse transcriptase inhibitors or protease inhibitors in a large observational cohort in the united States and Canada. J Int AIDS Soc. 2020;23(4):e25484\u2013e. https:\/\/doi.org\/10.1002\/jia2.25484.","journal-title":"J Int AIDS Soc"},{"issue":"6","key":"776_CR112","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1093\/cid\/ciz999","volume":"71","author":"PE Sax","year":"2020","unstructured":"Sax PE, Erlandson KM, Lake JE, McComsey GA, Orkin C, Esser S, et al. Weight gain following initiation of antiretroviral therapy: risk factors in randomized comparative clinical trials. Clin Infect Dis. 2020;71(6):1379\u201389. https:\/\/doi.org\/10.1093\/cid\/ciz999.","journal-title":"Clin Infect Dis"},{"issue":"9","key":"776_CR113","doi-asserted-by":"publisher","first-page":"e566","DOI":"10.1016\/S2352-3018(23)00136-4","volume":"10","author":"MN Ramgopal","year":"2023","unstructured":"Ramgopal MN, Castagna A, Cazanave C, Diaz-Brito V, Dretler R, Oka S, et al. Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a randomised, open-label, phase 3b, non-inferiority trial. Lancet HIV. 2023;10(9):e566\u201377. https:\/\/doi.org\/10.1016\/S2352-3018(23)00136-4.","journal-title":"Lancet HIV"},{"issue":"6","key":"776_CR114","doi-asserted-by":"publisher","first-page":"e369","DOI":"10.1016\/S2352-3018(24)00031-6","volume":"11","author":"JM Molina","year":"2024","unstructured":"Molina JM, Rizzardini G, Orrell C, Afani A, Calmy A, Oka S, et al. Switch to fixed-dose doravirine (100 mg) with islatravir (0.75 mg) once daily in virologically suppressed adults with HIV-1 on antiretroviral therapy: 48-week results of a phase 3, randomised, open-label, non-inferiority trial. Lancet HIV. 2024;11(6):e369\u201379. https:\/\/doi.org\/10.1016\/S2352-3018(24)00031-6.","journal-title":"Lancet HIV"},{"issue":"19","key":"776_CR115","doi-asserted-by":"publisher","first-page":"4504","DOI":"10.12998\/wjcc.v11.i19.4504","volume":"11","author":"M Gulinac","year":"2023","unstructured":"Gulinac M, Miteva DG, Peshevska-Sekulovska M, Novakov IP, Antovic S, Peruhova M, et al. Long-term effectiveness, outcomes and complications of bariatric surgery. World J Clin Cases. 2023;11(19):4504\u201312. https:\/\/doi.org\/10.12998\/wjcc.v11.i19.4504.","journal-title":"World J Clin Cases"},{"issue":"1","key":"776_CR116","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.orcp.2021.11.004","volume":"16","author":"Y Hua","year":"2022","unstructured":"Hua Y, Lou YX, Li C, Sun JY, Sun W, Kong XQ. Clinical outcomes of bariatric surgery - updated evidence. Obes Res Clin Pract. 2022;16(1):1\u20139. https:\/\/doi.org\/10.1016\/j.orcp.2021.11.004.","journal-title":"Obes Res Clin Pract"},{"key":"776_CR117","doi-asserted-by":"publisher","first-page":"e071027","DOI":"10.1136\/bmj-2022-071027","volume":"383","author":"AP Courcoulas","year":"2023","unstructured":"Courcoulas AP, Daigle CR, Arterburn DE. Long term outcomes of metabolic\/bariatric surgery in adults. BMJ. 2023;383:e071027. https:\/\/doi.org\/10.1136\/bmj-2022-071027.","journal-title":"BMJ"},{"issue":"8","key":"776_CR118","doi-asserted-by":"publisher","first-page":"2550","DOI":"10.1007\/s11695-018-3319-4","volume":"28","author":"K Akbari","year":"2018","unstructured":"Akbari K, Som R, Sampson M, Abbas SH, Ramus J, Jones G. The effect of bariatric surgery on patients with HIV infection: a literature review. Obes Surg. 2018;28(8):2550\u20139. https:\/\/doi.org\/10.1007\/s11695-018-3319-4.","journal-title":"Obes Surg"},{"issue":"2","key":"776_CR119","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/j.soard.2020.10.018","volume":"17","author":"L Gu","year":"2021","unstructured":"Gu L, Lin K, Du N, Ng DM, Lou D, Chen P. Differences in the effects of laparoscopic sleeve gastrectomy and laparoscopic Roux-en-Y gastric bypass on gut hormones: systematic and meta-analysis. Surg Obes Relat Dis. 2021;17(2):444\u201355. https:\/\/doi.org\/10.1016\/j.soard.2020.10.018.","journal-title":"Surg Obes Relat Dis"},{"issue":"3","key":"776_CR120","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1007\/s11695-017-2913-1","volume":"28","author":"P Jirapinyo","year":"2018","unstructured":"Jirapinyo P, Jin DX, Qazi T, Mishra N, Thompson CC. A meta-analysis of GLP-1 after Roux-En-Y gastric bypass: impact of surgical technique and measurement strategy. Obes Surg. 2018;28(3):615\u201326. https:\/\/doi.org\/10.1007\/s11695-017-2913-1.","journal-title":"Obes Surg"},{"issue":"1","key":"776_CR121","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1038\/s41522-020-0122-5","volume":"6","author":"ZE Ilhan","year":"2020","unstructured":"Ilhan ZE, DiBaise JK, Dautel SE, Isern NG, Kim YM, Hoyt DW, et al. Temporospatial shifts in the human gut Microbiome and metabolome after gastric bypass surgery. NPJ Biofilms Microbiomes. 2020;6(1):12. https:\/\/doi.org\/10.1038\/s41522-020-0122-5.","journal-title":"NPJ Biofilms Microbiomes"},{"issue":"10","key":"776_CR122","doi-asserted-by":"publisher","first-page":"3594","DOI":"10.1007\/s11695-024-07443-7","volume":"34","author":"M Fehervari","year":"2024","unstructured":"Fehervari M, Mitra AT, Sargsyan N, Davison N, Turner M, Efthimiou E, et al. Five-year outcomes of bariatric surgery vs. conservative weight management in people with HIV: a single-center tertiary care experience. Obes Surg. 2024;34(10):3594\u2013605. https:\/\/doi.org\/10.1007\/s11695-024-07443-7.","journal-title":"Obes Surg"},{"issue":"1","key":"776_CR123","doi-asserted-by":"publisher","first-page":"41","DOI":"10.4278\/ajhp.120606-QUAL-286","volume":"28","author":"JX Fan","year":"2013","unstructured":"Fan JX, Brown BB, Hanson H, Kowaleski-Jones L, Smith KR, Zick CD. Moderate to vigorous physical activity and weight outcomes: does every minute count? Am J Health Promot. 2013;28(1):41\u20139. https:\/\/doi.org\/10.4278\/ajhp.120606-QUAL-286.","journal-title":"Am J Health Promot"},{"issue":"2","key":"776_CR124","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.mayocp.2018.09.019","volume":"94","author":"S Rao","year":"2019","unstructured":"Rao S, Pandey A, Garg S, Park B, Mayo H, Despres JP, et al. Effect of exercise and pharmacological interventions on visceral adiposity: a systematic review and meta-analysis of long-term randomized controlled trials. Mayo Clin Proc. 2019;94(2):211\u201324. https:\/\/doi.org\/10.1016\/j.mayocp.2018.09.019.","journal-title":"Mayo Clin Proc"},{"issue":"1","key":"776_CR125","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1071\/SH09065","volume":"8","author":"GW Ng","year":"2011","unstructured":"Ng GW, Chan UM, Li PC, Wong WC. Can a mediterranean diet reduce the effects of lipodystrophy syndrome in people living with HIV? A pilot randomised controlled trial. Sex Health. 2011;8(1):43\u201351. https:\/\/doi.org\/10.1071\/SH09065.","journal-title":"Sex Health"},{"issue":"3","key":"776_CR126","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1016\/j.clnu.2020.08.038","volume":"40","author":"C Stradling","year":"2021","unstructured":"Stradling C, Thomas GN, Hemming K, Taylor S, Taheri S. Randomized parallel-group pilot trial (Best foods for your heart) comparing the effects of a mediterranean portfolio diet with a low saturated fat diet on HIV dyslipidemia. Clin Nutr. 2021;40(3):860\u20139. https:\/\/doi.org\/10.1016\/j.clnu.2020.08.038.","journal-title":"Clin Nutr"},{"issue":"10","key":"776_CR127","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1016\/j.metabol.2006.05.018","volume":"55","author":"ES Engelson","year":"2006","unstructured":"Engelson ES, Agin D, Kenya S, Werber-Zion G, Luty B, Albu JB, et al. Body composition and metabolic effects of a diet and exercise weight loss regimen on obese, HIV-infected women. Metabolism. 2006;55(10):1327\u201336. https:\/\/doi.org\/10.1016\/j.metabol.2006.05.018.","journal-title":"Metabolism"},{"issue":"1","key":"776_CR128","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1093\/cid\/cix238","volume":"65","author":"K Becofsky","year":"2017","unstructured":"Becofsky K, Wing EJ, McCaffery J, Boudreau M, Wing RR. A randomized controlled trial of a behavioral weight loss program for human immunodeficiency Virus-Infected patients. Clin Infect Dis. 2017;65(1):154\u20137. https:\/\/doi.org\/10.1093\/cid\/cix238.","journal-title":"Clin Infect Dis"},{"issue":"4","key":"776_CR129","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1002\/oby.21793","volume":"25","author":"DN Reeds","year":"2017","unstructured":"Reeds DN, Pietka TA, Yarasheski KE, Cade WT, Patterson BW, Okunade A, et al. HIV infection does not prevent the metabolic benefits of diet-induced weight loss in women with obesity. Obesity. 2017;25(4):682\u20138. https:\/\/doi.org\/10.1002\/oby.21793.","journal-title":"Obesity"},{"issue":"10","key":"776_CR130","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1111\/dme.13927","volume":"37","author":"AD Duncan","year":"2020","unstructured":"Duncan AD, Peters BS, Rivas C, Goff LM. Reducing risk of Type 2 diabetes in HIV: a mixed-methods investigation of the STOP-Diabetes diet and physical activity intervention. Diabet Med. 2020;37(10):1705\u201314. https:\/\/doi.org\/10.1111\/dme.13927.","journal-title":"Diabet Med"},{"key":"776_CR131","doi-asserted-by":"publisher","unstructured":"Ferrari Silva B, Jacques Past\u00f3rio E, Cristina Bueno G, Barnab\u00e9 Peres S, Marta Franzoi de Moraes S. Effects of 8 weeks of high-intensity interval training on hormonal and adipokines responses in people living with HIV: a non-controlled clinical trial. Arch Physiol Biochem. 2025;1\u201311. https:\/\/doi.org\/10.1080\/13813455.2025.2529291.","DOI":"10.1080\/13813455.2025.2529291"}],"container-title":["Current HIV\/AIDS Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11904-026-00776-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11904-026-00776-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11904-026-00776-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T17:04:11Z","timestamp":1771952651000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11904-026-00776-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,24]]},"references-count":131,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["776"],"URL":"https:\/\/doi.org\/10.1007\/s11904-026-00776-1","relation":{},"ISSN":["1548-3576"],"issn-type":[{"value":"1548-3576","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,24]]},"assertion":[{"value":"3 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6"}}